Sorrento TherapeuticsSRNE
13F holders, Q3 2025 (September 30)4holders +2
2new positions
0sold out
$0.00avg. 13F price*
At the end of Q3 2025, 4 institutions reported holding Sorrento Therapeutics Inc. (SRNE) in their 13F filings, up 2 from Q2 2025. 2 opened new positions and 0 sold out. The largest holders were Huntington National Bank ($19), Oakworth Capital, Inc. ($1) and Vermillion Wealth Management, Inc. ($0).
- Company
- Sorrento Therapeutics Inc.
- CUSIP
- 83587F202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $1 |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 420 shares bought, net +420 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Huntington National Bank | 0.00% | No change | 5,001 | $19 |
| Oakworth Capital, Inc. | 0.00% | New | 350 | $1 |
| Vermillion Wealth Management, Inc. | 0.00% | New | 70 | $0 |
| Financial Gravity Asset Management, Inc. | 0.00% | — | 18 | $0 |
"% of holder's portfolio" is SRNE's weight in each manager's 13F, not the share of Sorrento Therapeutics Inc. the manager owns.